The potential of CD36 as a therapeutic target for atherosclerosis and other complications of metabolic syndrome is therefore emphasized by our increasing knowledge of its mode of action and certainly warrants the development of novel alternatives aimed to correct for these metabolic defects. Here, CD36 is linked to metabolic syndrome.